Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38 results about "Tulobuterol" patented technology

Tulobuterol (INN) is a long-acting beta2-adrenergic receptor agonist, marketed in Japan as a transdermal patch under the name Hokunalin tape (ホクナリンテープ). Currently, it is only legal in 7 countries: Japan, Germany, China, South Korea, Bangladesh, Pakistan, and Venezuela. It is available in India also.

Tulobuterol transdermal patch with gradient drug release structure and preparation method of tulobuterol transdermal patch

PendingCN121971412AImprove the permeability coefficientModerate diffusion coefficientOrganic active ingredientsPharmaceutical non-active ingredientsTransdermal patchMesoporous silica
The invention discloses a tulobuterol transdermal patch with a gradient drug release structure and a preparation method of the tulobuterol transdermal patch, belongs to the technical field of transdermal drug delivery systems, and aims at solving the problems that an existing single-layer tulobuterol patch takes effect slowly and is insufficient in later-stage drug release power. The transdermal patch sequentially comprises a backing layer, a gradient medicine-containing substrate layer and an anti-sticking release layer from top to bottom, the gradient drug-containing matrix layer comprises a high-concentration top long-acting drug release layer containing tulobuterol-mesoporous silica nanoparticles and a silicone adhesive, a middle-concentration middle stable drug release layer containing an SIS hot melt adhesive, and a low-concentration bottom quick-acting contact layer containing a specific penetration enhancer composition and an acrylate adhesive from top to bottom in sequence. Through the synergistic effect of bottom-layer penetration promoting driving, middle-layer stable transition and top-layer nanometer storage cavern relay, the traditional concentration barrier is broken through, and rapid effect taking within 1-2 hours and stable-state long-acting drug release within 24 hours or above are perfectly considered.
Owner:ZHEJIANG HAIGETANG PHARM CO LTD